Trial Profile
A Randomized Phase II Study to Investigate the Efficacy of Rotations Between Abiraterone Acetate and Apalutamide Versus Sequential Administration in Chemo-naive Metastatic Castration Resistant Prostate Cancer Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AERA
- 23 Nov 2020 Planned End Date changed from 1 Dec 2021 to 31 Dec 2020.
- 23 Nov 2020 Planned primary completion date changed from 1 Jul 2021 to 31 Dec 2020.
- 15 Nov 2020 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018.